EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond HSV-1: Pseudorabies Virus as a Next-Generation Seronegative Backbone for Oncolytic Virotherapy

Anna Aubareda, Silvia Gómez-Sebastián

Microorganisms · 12.11.2026 · 14 (11) · 2627

DOI: 10.3390/microorganisms14112627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 12.11.2026. Verfasst von Anna Aubareda und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic virotherapy has emerged as a promising strategy to combat cancer by exploiting viruses that selectively replicate in and destroy tumour cells. Among herpesviruses, herpes simplex virus type 1 (HSV-1) has served as the most extensively studied platform for the development of genetically engineered oncolytic viruses (OVs). However, its neurovirulence and widespread human seroprevalence pose safety concerns. Pseudorabies virus (PRV), a swine alphaherpesvirus not naturally pathogenic to humans, offers a compelling alternative. This review explores PRV’s biological features, mechanisms of cell entry, and genetic manipulability, highlighting its potential as a safe and versatile oncolytic platform. Advances in attenuation strategies, promoter targeting, and tropism modulation have enabled the development of recombinant PRVs with tumour-selective replication and reduced neurovirulence. Furthermore, PRV vectors armed with immunomodulatory transgenes have demonstrated potent antitumour efficacy and immune activation in preclinical models. Collectively, these findings position PRV as a promising candidate for next-generation oncolytic virotherapy, with potential to complement existing platforms.

Zitieren

APA

Aubareda, A., & Gómez-Sebastián, S. (2026). Beyond HSV-1: Pseudorabies Virus as a Next-Generation Seronegative Backbone for Oncolytic Virotherapy. Microorganisms, 14(11), 2627. https://doi.org/10.3390/microorganisms14112627

Vancouver

Aubareda A, Gómez-Sebastián S. Beyond HSV-1: Pseudorabies Virus as a Next-Generation Seronegative Backbone for Oncolytic Virotherapy. Microorganisms. 2026;14(11):2627. doi:10.3390/microorganisms14112627

BibTeX
@article{Aubareda2026,
  author = {Aubareda, Anna and Gómez-Sebastián, Silvia},
  title = {Beyond HSV-1: Pseudorabies Virus as a Next-Generation Seronegative Backbone for Oncolytic Virotherapy},
  journal = {Microorganisms},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {2627},
  doi = {10.3390/microorganisms14112627}
}
Kostenlos starten →